Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bipolar depression: management options.

Gin S Malhi1, Philip B Mitchell, Shahzad Salim

  • 1School of Psychiatry, University of New South Wales, Randwick, Sydney, New South Wales, Australia.

CNS Drugs
|December 7, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Torture exposure and the functional brain: investigating disruptions to intrinsic network connectivity using resting state fMRI.

Translational psychiatry·2022
Same author

Exploring interleukin-6, lipopolysaccharide-binding protein and brain-derived neurotrophic factor following 12 weeks of adjunctive minocycline treatment for depression.

Acta neuropsychiatrica·2021
Same author

Preventing suicide by young people requires integrative strategies.

The Medical journal of Australia·2021
Same author

Questions in Psychiatry (QuiP): Using your Apple all day, might keep the doctor away?

Bipolar disorders·2021
Same author

Novel insights into irritability: the relationship between subjective experience, age and mood.

BJPsych open·2021
Same author

Default-mode and fronto-parietal network connectivity during rest distinguishes asymptomatic patients with bipolar disorder and major depressive disorder.

Translational psychiatry·2021
Same journal

Impact of Omaveloxolone on Serum Lipids in Patients with Friedreich Ataxia: A 1-Year Real-World Analysis.

CNS drugs·2026
Same journal

Emerging Pharmacological Strategies for Trigeminal Neuralgia.

CNS drugs·2026
Same journal

Psychiatric Symptoms Associated with Corticosteroid Use: A Systematic Review and Meta-analysis.

CNS drugs·2026
Same journal

Anti-CD20 Therapies in Pediatric Acquired Demyelinating Syndromes: Evidence Across MS, AQP4-IgG-Positive NMOSD and MOGAD.

CNS drugs·2026
Same journal

Isoform-Specific NaV Modulation in Painful Chemotherapy-Induced Neuropathy: Promise, Limitations, and a Clinical Agenda.

CNS drugs·2026
Same journal

Correction: Seletracetam Revisited: A Missed Opportunity for Effective Epilepsy Therapy.

CNS drugs·2026
See all related articles

Bipolar depression, often neglected, is the primary mood state in bipolar disorder. Effective treatments include antidepressants and mood stabilizers, with lamotrigine showing recent promise for acute and long-term management.

Area of Science:

  • Psychiatry
  • Neuroscience
  • Pharmacology

Background:

  • Bipolar depression is the predominant mood state in bipolar disorder, yet historically receives less research and clinical focus than mania.
  • Early research often conflated bipolar depression with unipolar depression, leading to the adoption of unproven treatments.
  • This neglect has resulted in a lack of robust evidence for many treatments used in bipolar depression management.

Purpose of the Study:

  • To review the current understanding and management strategies for bipolar depression.
  • To highlight the efficacy and risks associated with various pharmacological interventions.
  • To emphasize the importance of prompt diagnosis and tailored treatment for this disabling condition.

Main Methods:

  • Review of existing literature on bipolar depression treatments.

Related Experiment Videos

  • Analysis of the efficacy and side-effect profiles of antidepressants (SSRIs, bupropion, TCAs, MAOIs) and mood stabilizers (lithium, carbamazepine, valproate, lamotrigine).
  • Discussion of clinical management strategies based on the context of depressive episodes (de novo vs. breakthrough).

    • Main Results:

    • Antidepressants like SSRIs, bupropion, TCAs, and MAOIs are effective but carry a small risk of mood instability.
    • Mood stabilizers such as lithium, carbamazepine, and valproate show modest acute antidepressant effects, with lithium having the strongest data but slow onset.
    • Lamotrigine is emerging as a potentially effective agent for both acute and prophylactic treatment of bipolar depression.

    Conclusions:

    • Clinical management of bipolar depression requires a combination of antidepressants and mood stabilizers, tailored to the specific episode context.
    • Breakthrough episodes may necessitate medication adjustments, augmentation, or alternative strategies like ECT.
    • Prompt diagnosis and effective management of bipolar depression are crucial due to its disabling nature and significant suicide risk.